Abstract
Increasing evidence supports that microRNA (miRNA) plays a significant functional role in cancer progression by directly regulating respective targets. In this study, the expression levels of miR-105-1 and its target gene were analyzed using genes microarray and hierarchical clustering analysis followed by validation with quantitative RT-PCR in hepatocellular carcinoma (HCC) and normal liver tissues. We examined the expression of nuclear receptor coactivator 1 (NCOA1), the potential target gene of miR-105-1, following the transfection of miR-105-1 mimics or inhibitors. Our results showed that miR-105-1 was downregulated in HCC tissues when compared with normal liver tissues and patients with lower miR-105-1 expression had shorter overall survival (OS) and progression free survival (PFS). Moreover, NCOA1 was confirmed to be a direct target of miR-105-1. Furthermore, concomitant high expression of NCOA1 and low expression of miR-105-1 correlated with a shorter median OS and PFS in HCC patients. In conclusion, our results provide the first evidence that NCOA1 is a direct target of miR-105-1 suggesting that NCOA1 and miR-105-1 may have potential prognostic value and may be useful as tumor biomarkers for the diagnosis of HCC patients.
Highlights
Hepatocellular carcinoma (HCC) is one of the world’s most common malignant tumors and is characterized by poor prognosis and high mortality rates [1]
Our results showed that miR-105-1 was downregulated in hepatocellular carcinoma (HCC) tissues when compared with normal liver tissues and patients with lower miR-1051 expression had shorter overall survival (OS) and progression free survival (PFS)
We found 14 upregulated and 24 downregulated miRNAs (fold change (FC) ≥ 2 or ≤ 0.5, P < 0.01) (Figure 1A) in HCC tissues when compared with normal liver tissues
Summary
Hepatocellular carcinoma (HCC) is one of the world’s most common malignant tumors and is characterized by poor prognosis and high mortality rates [1]. While recent advancements in medical imaging have resulted in early diagnosis of HCC patients, www.impactjournals.com/oncotarget clinical prognosis of HCC remains dire despite the use of targeted therapies [3,4,5]. Previous studies have identified various miRNAs in HCC patients, including miR-1, miR9, miR-15b, miR-130b, miR-16, miR-18a, and miR-21 [10,11,12,13]. MiR-105-1 has been detected in many tumors, such as breast cancer, prostate tumor, human glioma, and gastric cancer [14,15,16,17], its role and clinical significance have not been clarified in HCC. In this study, we explored the clinical significance and target gene of miR-105-1 as a prognostic biomarker for HCC patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
